Biocon received approval to sell Insulin Glargine in Japan


Posted on:01 Apr 2016 10:19:18

Biocon received approval to sell Insulin Glargine in Japan
01 April 2016 Current Affairs: Biocon Ltd on 28 March 2016 announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan approved its biosimilar Insulin Glargine.The approval for Insulin Glargine was obtained post successful completion of initial development by Biocon and local Phase III Clinical Studies in over 250 Type 1 Diabetes patients by its partner FUJIFILM Pharma Co. Ltd (FFP) in Japan.The product will be available in Japan in 2017 in the form of disposable pen with 3 ml of 100IU Insulin Glargine. At present, it is available in India with the brand name Basalog One.With this launch, the company is also aiming to capture a significant share of the Japanese Glargine market of 144 million US dollars.It is the second largest market outside of North America and Europe and is largely dominated by disposable pens.Biocon Ltd is India's largest and fully-integrated, innovation-led biopharmaceutical company.The Bengaluru-based company serves its customers in over 100 countries. Its products are focused on chronic diseases like autoimmune, diabetes and cancer.It has successfully developed and taken a range of novel biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin and analogs from 'Lab to Market'.It has a rich pipeline of biosimilars and novel biologics at various stages of development including high potential oral insulin.


Subscribe to Current Affairs

Enter your email to get daily current affairs

Current Affairs June 2017

26 JUNE
NEWS
24 JUNE
NEWS
23 JUNE
NEWS
22 JUNE
NEWS

Current Affairs May 2017

31 MAY
NEWS
30 MAY
NEWS
29 MAY
NEWS
27 MAY
NEWS

Current Affairs April 2017

29 APRIL
NEWS
28 APRIL
NEWS
27 APRIL
NEWS
26 APRIL
NEWS